Latest Headlines

Latest Headlines

Almirall deepens its dermatology dive with a $386M deal

Spanish drugmaker Almirall, moving on from its former focus on respiratory therapies, is beefing up its dermatology pipeline with a buyout of Switzerland's Poli Group.

Petco abandons IPO plan in favor of $4.6B buyout

Back in August, retail chain Petco filed for an initial public offering, emphasizing its newfound focus on animal health. But on November 23, the company said that it will instead be acquired for $4.6 billion by the private equity firms CVC Capital Partners and the Canadian Pension Plan Investment Board.

Mylan may soon find itself wrestling former target Perrigo for deals

Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up against its former target if it wants to pursue a replacement buy.

Spurned Shire preps new takeover offer for longtime target Baxalta

Last month, Shire said it still believed an acquisition for Baxalta--a target that rejected it almost four months back--would make a "highly strategic combination." And now, it's preparing to follow up.

Trump, Clinton lash out at Pfizer over Allergan deal agreement

Pfizer may be amped about its brand-new agreement to tie up with Allergan and move to tax-advantaged Ireland. But U.S. politicians? They're not so thrilled with the idea.

Synerlab buys contract manufacturing developer Alcala Farma for undisclosed price

Synerlab, a French pharmaceutical manufacturer, has purchased Spain-based contract development and manufacturing company Alcala Farma for an undisclosed amount.

With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards?

Both Pfizer and Allergan have a history of doing "transformational" deals--and those can come along with serious layoffs. So now that they've joined hands in a $160 billion merger agreement, is there reason to expect any different?

Perrigo gets AstraZeneca Crohn's treatment as it moves past Mylan's failed takeover attempt

After finally turning back the long-running takeover attempt by Mylan, Perrigo assured shareholders they could expect "industry-leading future growth prospects." In its first move toward delivering on that promise, the OTC specialist said today it will buy the U.S. rights to AstraZeneca's Crohn's disease drug Entocort.

With Pfizer and Allergan set for a $160B megamerger, what becomes of R&D?

Pfizer and Allergan have confirmed what many long suspected, agreeing to merge in a $160 billion deal that gives the former a much-desired tax break and the latter a predictable final resting place. But the combination Pfizer's penchant for postdeal job cuts and Allergan's well-established aversion to early-stage research paints a cloudy picture of how R&D will get done at what would be the world's new largest drugmaker.

UPDATED: Pfizer finally gets its inversion with $160B Allergan megamerger agreement

The agreement's been made: The boards at Pfizer and Allergan have ratified a megamerger--worth about $160 billion--that will create the world's biggest pharma company and send Pfizer overseas, the companies announced on Monday.